Treatment News : HIV Meds Can Still Benefit Those with Triple-Class Failure

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 30, 2013

HIV Meds Can Still Benefit Those with Triple-Class Failure

People with HIV who have experienced triple-class treatment failure can still reap health benefits from antiretroviral (ARV) treatment if the medications lower their viral load even somewhat, aidsmap reports. Publishing the results of their research in the Journal of Infectious Diseases, European scientists from the COHERE study found that there is a direct, linear correlation between lower viral loads and higher CD4 counts.

The researchers analyzed records from 2,424 HIV-positive people who had experienced failure in all three classes of ARVs since 1998. (The newer classes of ARVs made up a small fraction of the therapies utilized: Only 7 percent of the participants took fusion inhibitors, 9 percent integrase inhibitors and 1 percent CCR5 inhibitors.) After creating a mathematical model that projected changes in CD4 counts assuming a baseline of 300 cells after triple-class failure, the scientists found that those with a viral load of 100 would have a CD4 count of 386 after two years. For each additional power of 10 in viral load, the CD4 count after two years would drop steadily—so that those with a viral load of 1 million would likely have a CD4 count of 213.

“While in those with high CD4 count it may be possible to wait until new active drugs are available, for those with low CD4 count it is important to use the regimen most likely to achieve maximal viral suppression,” the researchers write, adding that for “an individual who is not fully adherent, any increase in adherence is likely to provide immediate benefits in terms of reduced risk of clinical disease.”

For the aidsmap story, click here

Search: HIV, antiretrovirals, triple-class treatment failure, viral load, treatment benefit, CD4, aidsmap, COHERE study, Journal of Infectious Diseases, integrase inhibitors, CCR5 inhibitors, fusion inhibitors.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.